| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6183236 | Gynecologic Oncology | 2015 | 5 Pages |
Abstract
The use of a chemoresponse assay to inform treatment decisions in recurrent ovarian cancer patients has the potential to be cost-effective in both platinum-sensitive and platinum-resistant patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Victoria Plamadeala, Joseph L. Kelley, John K. Chan, Thomas C. Krivak, Michael J. Gabrin, Stacey L. Brower, Matthew A. Powell, Thomas J. Rutherford, Robert L. Coleman,